

# Matthew L Senjem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2064090/publications.pdf>

Version: 2024-02-01

252  
papers

19,630  
citations

12303

69  
h-index

13727

129  
g-index

309  
all docs

309  
docs citations

309  
times ranked

15241  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>APOE<math>\epsilon</math>4</i> influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 784-796.	0.4	7
2	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	1.5	12
3	<sup>1</sup> H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	1.5	9
4	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3
5	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	1.5	15
6	Left-Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T1 Weighted MRI Images. <i>Journal of Magnetic Resonance Imaging</i> , 2022, , .	1.9	3
7	A computational model of neurodegeneration in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1643.	5.8	32
8	The Overlap Index as a means of evaluating early tau-PET signal reliability. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263136.	2.8	5
9	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	2.2	11
10	Impact of material homogeneity assumption on cortical stiffness estimates by MR elastography. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 916-929.	1.9	7
11	Comparison of <sup>11</sup> C-Pittsburgh Compound B and <sup>18</sup> F-Flutemetamol White Matter Binding in PET. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1239-1244.	2.8	7
12	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	4.5	29
13	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	12
14	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	1.5	5
15	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	5.3	52
16	CSF phosphorylated tau as an indicator of subsequent tau accumulation. <i>Neurobiology of Aging</i> , 2022, 117, 189-200.	1.5	4
17	Face recognition from research brain PET: An unexpected PET problem. <i>NeuroImage</i> , 2022, 258, 119357.	2.1	6
18	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	2.1	63
20	Association of Initial $\beta$ -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	4.5	27
21	Phonological Errors in Posterior Cortical Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 195-203.	0.7	8
22	$\beta$ -Amyloid PET and $^{123}\text{I}$ -FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.5	13
23	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	1.4	27
24	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	1.0	13
25	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	2.1	3
26	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
27	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
28	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	5.8	34
29	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	2.2	4
30	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	1.5	12
31	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
32	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
33	Relationships between $\beta$ -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	2.1	15
34	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	1.5	11
35	Sleep quality and cortical amyloid- $\beta$ deposition in postmenopausal women of the Kronos early estrogen prevention study. <i>NeuroReport</i> , 2021, 32, 326-331.	0.6	5
36	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	1.2	2
38	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	2.4	31
39	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	1.2	1
40	The Overlap Index: A new means for early detection of serial tau PET signal change. Alzheimer's and Dementia, 2021, 17, .	0.4	0
41	Relationship of <i>APOE</i> , age, amyloid and clinical phenotype in Alzheimer disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
42	Comparison of Pittsburgh compound- $\beta$ and flutemetamol white matter binding. Alzheimer's and Dementia, 2021, 17, .	0.4	0
43	Baseline CSF phosphorylated tau as an indicator of subsequent tau accumulation on tau PET. Alzheimer's and Dementia, 2021, 17, .	0.4	0
44	Optimizing software methods for measuring flortaucipir SUVR change over time. Alzheimer's and Dementia, 2021, 17, .	0.4	0
45	Higher systolic and diastolic blood pressures are associated with loss of white matter integrity in postmenopausal women of the KEEPS Continuation Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
46	An examination of atypical primary progressive aphasia variants. Alzheimer's and Dementia, 2021, 17, .	0.4	0
47	Tau-positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
48	$\beta$ -Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
49	$\beta$ -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
50	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
51	Longitudinal Amyloid- $\beta$ PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
52	Sensitivity-Specificity of Tau and Amyloid $\beta$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
53	Functional connectivity is associated with tau spreading in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e037681.	0.4	0
54	Multiple sclerosis is associated with lower amyloid but normal tau burden on PET. Alzheimer's and Dementia, 2020, 16, e039179.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Disrupted brain dynamics across the Alzheimer's disease spectrum is related to tau accumulation. <i>Alzheimer's and Dementia</i> , 2020, 16, e040583.	0.4	0
56	Progressive dysexecutive syndrome due to Alzheimer's disease: A description of 55 cases and comparisons to other clinical AD phenotypes. <i>Alzheimer's and Dementia</i> , 2020, 16, e040622.	0.4	1
57	Effect of disproportionately enlarged subarachnoid space hydrocephalus (DESH) on cognition. <i>Alzheimer's and Dementia</i> , 2020, 16, e042304.	0.4	0
58	Asymmetric caudate hypometabolism in the absence of frontal involvement on FDGPET in patients with semantic dementia and behavioral symptoms. <i>Alzheimer's and Dementia</i> , 2020, 16, e045393.	0.4	1
59	Quantitative susceptibility mapping of substantia nigra in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e046236.	0.4	0
60	CD33, MEF2C, and SORL1 are associated with variability in macroscale functional brain architecture in AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046573.	0.4	0
61	Neuroimaging and neuropsychological findings in MAPT N279K mutation phenoconverters. <i>Alzheimer's and Dementia</i> , 2020, 16, e046759.	0.4	0
62	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	3.7	45
63	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	1.5	81
64	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27
65	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
66	Identification of Normal Pressure Hydrocephalus by Disease-Specific Patterns of Brain Stiffness and Damping Ratio. <i>Investigative Radiology</i> , 2020, 55, 200-208.	3.5	32
67	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	1.5	3
68	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
69	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
70	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	1.5	14
71	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	2.8	17
72	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14

#	ARTICLE	IF	CITATIONS
73	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
74	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. <i>Brain and Language</i> , 2020, 204, 104773.	0.8	15
75	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.5	13
76	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	1.9	53
77	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	0.8	29
78	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	1.8	22
79	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
80	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 56-61.	1.1	19
81	The bivariate distribution of amyloid- $\beta^2$ and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
82	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	1.0	39
83	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	3.7	37
84	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	3.7	33
85	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	3.8	223
86	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 452-461.	0.8	26
87	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
88	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
89	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	3.7	126
90	Investigation of white matter PiB uptake as a marker of white matter integrity. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 678-688.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	1.4	54
92	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 675-685.	0.4	36
93	Neural correlates of domain-specific cognitive decline. <i>Neurology</i> , 2019, 92, e1051-e1063.	1.5	12
94	Entorhinal cortex tau, amyloid- $\beta^2$ , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	3.7	68
95	O2â€08â€01: ANTEâ€MORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NONâ€FTLD OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P553.	0.4	0
96	ICâ€Pâ€078: ALTERED CSF DYNAMICS INFLUENCE DISCREPANCIES BETWEEN CSF AND PET BIOMARKERS OF AMYLOID. <i>Alzheimer's and Dementia</i> , 2019, 15, P70.	0.4	0
97	ICâ€Pâ€127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. <i>Alzheimer's and Dementia</i> , 2019, 15, P104.	0.4	3
98	O2â€07â€01: SLEEP QUALITY AND BETAâ€AMYLOID DEPOSITION IN RECENTLY MENOPAUSAL WOMEN PARTICIPATING IN THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS). <i>Alzheimer's and Dementia</i> , 2019, 15, P551.	0.4	1
99	O4â€12â€01: TAU PET IMAGING CORRELATES WITH NEUROPATHOLOGY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1264.	0.4	0
100	ICâ€O2â€03: MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AVâ€1451 UPTAKE. <i>Alzheimer's and Dementia</i> , 2019, 15, P2.	0.4	0
101	ICâ€O4â€02: ANTEMORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NONâ€FTLD OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P5.	0.4	0
102	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P30.	0.4	0
103	ICâ€Pâ€027: DECODING GLUCOSE METABOLISM IN ALZHEIMER'S DISEASE REVEALS MACROâ€SCALE BRAIN ORGANIZATION RELATED TO DISEASE EXPRESSION. <i>Alzheimer's and Dementia</i> , 2019, 15, P34.	0.4	0
104	Association of Longitudinal $\beta^2$ -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22
105	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.5	53
106	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	2.2	33
107	The influence of $\beta^2$ -amyloid on [ <sup>18</sup> F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.5	10
108	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	4.5	69

#	ARTICLE	IF	CITATIONS
109	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	1.2	48
110	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	1.7	25
111	Joint associations of $\beta$ -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	1.5	27
112	[ $^{18}\text{F}$ ] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. <i>Journal of Neurology</i> , 2018, 265, 1079-1088.	1.8	29
113	White Matter Reference Region in PET Studies of $^{11}\text{C}$ -Pittsburgh Compound B Uptake: Effects of Age and Amyloid- $\beta$ Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	2.8	37
114	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.5	57
115	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [ $^{18}\text{F}$ ]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	1.2	45
116	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	1.2	19
117	[ $^{18}\text{F}$ ]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	2.8	73
118	Tau-PET imaging with [ $^{18}\text{F}$ ]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
119	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.5	24
120	In vivo $^{18}\text{F}$ -AV-1451 tau PET signal in <i>MAPT</i> mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.5	60
121	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	1.1	27
122	[ $^{18}\text{F}$ ]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
123	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	3.7	42
124	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218
125	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
126	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	3.7	309



#	ARTICLE	IF	CITATIONS
127	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	1.4	34
128	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	2.8	49
129	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. <i>European Journal of Neurology</i> , 2018, 25, 1352-1357.	1.7	12
130	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. <i>NeuroImage: Clinical</i> , 2018, 18, 897-902.	1.4	33
131	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	1.4	31
132	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	0.8	106
133	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
134	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.3	4
135	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. <i>Scientific Reports</i> , 2018, 8, 7421.	1.6	9
136	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. <i>Neurocase</i> , 2018, 24, 111-120.	0.2	25
137	Contributions of imprecision in $\text{PET} \rightarrow \text{MRI}$ rigid registration to imprecision in amyloid $\text{PET} \rightarrow \text{SUVR}$ measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	1.9	26
138	Age-specific and sex-specific prevalence of cerebral $\beta$ -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
139	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	1.5	158
140	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. <i>Journal of Neurology</i> , 2017, 264, 938-945.	1.8	24
141	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	1.2	86
142	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	1.1	162
143	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.5	30
144	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	4.9	159
146	<sup>18</sup> F-AV-1451 tau and <sup>125</sup> I-amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	2.8	152
147	[ <sup>18</sup> F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	2.2	136
148	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. <i>NeuroImage</i> , 2017, 144, 113-127.	2.1	59
149	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
150	<sup>18</sup> F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 632-638.	2.8	91
151	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. <i>Cortex</i> , 2017, 90, 138-148.	1.1	22
152	[P2415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. <i>Alzheimer's and Dementia</i> , 2017, 13, P792.	0.4	33
153	[CâP122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. <i>Alzheimer's and Dementia</i> , 2017, 13, P93.	0.4	22
154	Comparison of [ <sup>18</sup> F]Flutemetamol and [ <sup>11</sup> C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	1.4	30
155	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	1.2	24
156	Regional brain stiffness changes across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2016, 10, 283-290.	1.4	152
157	MR Elastography Demonstrates Increased Brain Stiffness in Normal Pressure Hydrocephalus. <i>American Journal of Neuroradiology</i> , 2016, 37, 462-467.	1.2	77
158	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.5	47
159	[ <sup>18</sup> F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
160	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	1.4	249
161	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
162	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.5	22

#	ARTICLE	IF	CITATIONS
163	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
164	Early Postmenopausal Transdermal 17 $\beta$ -Estradiol Therapy and Amyloid- $\beta$ Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 547-556.	1.2	94
165	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 29-35.	1.1	18
166	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	2.2	32
167	Regional $\beta$ -amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. <i>European Journal of Neurology</i> , 2016, 23, 313-319.	1.7	17
168	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	4.9	104
169	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	1.4	10
170	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.5	71
171	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.4	58
172	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	1.2	27
173	TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. <i>Annals of Neurology</i> , 2015, 78, 697-709.	2.8	96
174	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	0.8	49
175	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	1.5	83
176	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. <i>European Journal of Neurology</i> , 2015, 22, 745-752.	1.7	106
177	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	1.1	133
178	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	1.8	10
179	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.4	142
180	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	3.7	222

#	ARTICLE	IF	CITATIONS
181	Age, Sex, and <i>APOE</i> $\epsilon$ 4 Effects on Memory, Brain Structure, and $\beta$ -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	4.5	305
182	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	1.5	35
183	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. <i>NeuroImage</i> , 2015, 113, 61-69.	2.1	38
184	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
185	Role of $\beta$ -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	4.5	23
186	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015, 123, 149-164.	2.1	63
187	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	1.5	113
188	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.5	45
189	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.5	73
190	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	4.5	57
191	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.5	143
192	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	1.5	29
193	Progranulin-associated PiB-negative logopenic primary progressive aphasia. <i>Journal of Neurology</i> , 2014, 261, 604-614.	1.8	69
194	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	1.1	32
195	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.4	14
196	<i>APOE</i> $\epsilon$ 4 influences $\beta$ -Amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.4	31
197	Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia. <i>European Journal of Neurology</i> , 2014, 21, 1040-1043.	1.7	9
198	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	3.7	134

#	ARTICLE	IF	CITATIONS
199	Age-specific population frequencies of cerebral $\beta$ -amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	4.9	297
200	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	3.9	336
201	$^{18}$ F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	1.5	108
202	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	2.1	155
203	Rates of $\beta$ -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.5	119
204	Identification of an atypical variant of logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 139-144.	0.8	49
205	Modeling trajectories of regional volume loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1117-1124.	2.2	36
206	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.5	95
207	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 1681-1689.	1.5	58
208	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. <i>Neurobiology of Aging</i> , 2013, 34, 636-639.	1.5	54
209	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	1.4	44
210	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 127-134.	0.8	53
211	Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2013, 20, 629-637.	1.7	47
212	Brain $\beta$ -amyloid load approaches a plateau. <i>Neurology</i> , 2013, 80, 890-896.	1.5	335
213	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. <i>Neurology</i> , 2013, 80, 911-918.	1.5	86
214	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. <i>Brain and Language</i> , 2013, 125, 245-252.	0.8	66
215	Brain injury biomarkers are not dependent on $\beta$ -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	2.8	155
216	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. <i>Brain</i> , 2013, 136, 455-470.	3.7	37

#	ARTICLE	IF	CITATIONS
217	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , 2013, 80, 2130-2137.	1.5	46
218	Elevated occipital $\beta$ -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	0.9	28
219	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. <i>Neurology</i> , 2013, 81, 337-345.	1.5	142
220	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.5	182
221	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With $\beta$ -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	4.5	65
222	Measuring the Characteristic Topography of Brain Stiffness with Magnetic Resonance Elastography. <i>PLoS ONE</i> , 2013, 8, e81668.	1.1	125
223	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer's Type. <i>PLoS ONE</i> , 2013, 8, e62471.	1.1	100
224	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	3.7	355
225	Indicators of amyloid burden in a population-based study of cognitively normal elderly. <i>Neurology</i> , 2012, 79, 1570-1577.	1.5	146
226	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 856-67.	4.9	99
227	Ante mortem amyloid imaging and $\beta$ -amyloid pathology in a case with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 878-885.	1.5	69
228	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	1.5	162
229	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	3.7	325
230	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	4.9	355
231	Non-Stationarity in the "Resting Brain"™-Modular Architecture. <i>PLoS ONE</i> , 2012, 7, e39731.	1.1	382
232	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. <i>Brain</i> , 2012, 135, 2470-2477.	3.7	64
233	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.5	91
234	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012, 71, 765-775.	2.8	520

#	ARTICLE	IF	CITATIONS
235	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	2.1	90
236	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 599-605.	1.1	146
237	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. <i>Neurobiology of Aging</i> , 2011, 32, 1531-1541.	1.5	105
238	Transforming cerebrospinal fluid A $\beta$ 242 measures into calculated Pittsburgh compound B units of brain A $\beta$ amyloid. , 2011, 7, 133-141.		85
239	Gray matter correlates of behavioral severity in progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 493-498.	2.2	43
240	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	3.7	45
241	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. <i>Archives of Neurology</i> , 2010, 67, 1379-85.	4.9	146
242	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. <i>American Journal of Neuroradiology</i> , 2010, 31, 1247-1253.	1.2	48
243	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2010, 133, 3336-3348.	3.7	455
244	Functional magnetic resonance imaging changes in amnesic and nonamnesic mild cognitive impairment during encoding and recognition tasks. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 372-382.	1.2	73
245	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2009, 6, 106-117.	0.8	47
246	Comparison of <sup>18</sup> F-FDG and PiB PET in Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 878-886.	2.8	183
247	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. <i>Brain</i> , 2009, 132, 2932-2946.	3.7	277
248	Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. <i>Brain</i> , 2009, 132, 1355-1365.	3.7	975
249	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	2.1	391
250	<sup>11</sup> C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	3.7	819
251	Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. <i>Neurology</i> , 2006, 66, 102-104.	1.5	351
252	Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. <i>NeuroImage</i> , 2005, 26, 600-608.	2.1	169